Recent Company News

• 04:14 AM ET Sep 15, 2025
  

  StreetAccount Summary - Trading higher/lower: EU mid-morning

• 02:31 AM ET Mar 12, 2026
  

  Biophytis-Lynxkite alliance expands to turbocharge AI-driven drug discovery for next generation longevity therapeutics (€0.03, 0.00)

• 01:47 AM ET Jan 28, 2026
  

  Biophytis enters strategic agreement in Asia and secures $20M for launch of Phase 3 trial of BIO101 in sarcopenia (€0.06, 0.00)

• 06:20 PM ET Oct 30, 2025
  

  Biophytis reports H1 net income (€3.5M) vs year-ago (€5.8M) (€0.11, 0.00)

• 01:09 AM ET Oct 13, 2025
  

  Biophytis and a consortium of Asian investors plan to form JV to develop and exclusively commercialize BIO101 in China, Japan, and Korea (€0.15, 0.00)

• 01:04 AM ET Sep 15, 2025
  

  Biophytis Secures public funding in Brazil for Obesity Phase 2 Trial and Signs agreements with Leading local Clinical Partners (€0.17, 0.00)